Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + axitinib
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Pembrolizumab + axitinib is a combination therapy that targets two different pathways in cancer treatment. Pembrolizumab is a humanized monoclonal antibody that blocks PD-1 and PD-L1 interaction, enhancing and prolonging immune response to the tumor microenvironment. Axitinib is a selective tyrosine kinase inhibitor of VEGF receptors that targets tumor angiogenesis. This combination was approved by the FDA in April 2019 for the first-line treatment of patients with advanced renal cell carcinoma (RCC). In clinical trials, the combination significantly improved overall survival, progression-free survival, and objective response rate compared to sunitinib, with benefits observed across all risk groups regardless of PD-L1 expression.
- Brand names
- Keytruda + Inlyta
- Other names
- pembrolizumab plus axitinibaxitinib and pembrolizumab
02
Targets
VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR4 (Vascular endothelial growth factor Receptor-3)VEGFR2 (Vascular endothelial growth factor receptor 2)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on pembrolizumab + axitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + axitinib.